Novartis and Versant to form biotech venture Borealis Biosciences
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Subscribe To Our Newsletter & Stay Updated